Illumina Inc, San Diego, and Genomics England, London, have announced that Illumina is the primary vendor for variant interpretation and reporting software for tumor and matched normal samples characterized as part of the UK’s 100,000 Genomes Project.
In a little over a year since Illumina announced the bioinformatics and clinical interpretation partnership with Genomics England, the partnership has now set unified standards for data and analysis practices using BaseSpace Variant Interpreter software for tumor variant review.
Garret Hampton, Illumina.
“We are very pleased to be enabling cutting-edge variant interpretation and precision genomics for the NHS in cancer,” says Garret Hampton, executive vice president of the clinical genomics group at Illumina. “This is a major milestone for our population sequencing efforts, and demonstrates Illumina’s commitment to developing software that delivers on the promise of transformative healthcare through sequencing.”
Sir John Chisholm, Genomics England.
“We believe that whole genome sequencing will underpin the future of cancer care—providing greater understanding of the disease and a fuller prognostic picture for patients,” says Sir John Chisholm, executive chair at Genomics England. “Illumina’s variant interpretation and reporting software will enable us to deliver better insights from the 100,000 Genomes Project. We are delighted to be working with Illumina alongside our other delivery partners to drive forward genomic research and support our ambitions of transforming NHS patient care.”
BaseSpace Variant Interpreter (beta) enables researchers to perform rapid annotation, filtering, and interpretation of genomic data. Its variant-to-report workflow helps summarize findings into structured reports within a software framework focused on data security, compliance, and operational efficiency.
For more information, visit Illumina.
